Search | IOVS | ARVO Journals

Showing 1 – 20 of 89

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1157. doi:

ARVO Annual Meeting Abstract June 2020

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Grace Tsai; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1909. doi:

ARVO Annual Meeting Abstract June 2020

Classification of disease severity in Retinitis Pigmentosa

Bushra Usmani; Mustafa Iftikhar; Marili Lemus; Peter A Campochiaro; Jose Alain Sahel; Hendrik P Scholl; Syed Mahmood Ali Shah

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3024. doi:

ARVO Annual Meeting Abstract June 2020

Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors

Kun Ding; Jikui Shen; Sean Hackett; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4490. doi:

ARVO Annual Meeting Abstract July 2019

Suprachoroidal AAV8-Vectored Gene Transfer Provides Widespread Transgene Expression in RPE and Retina

Kun Ding; Jikui Shen; Zibran Hafiz; Sean Hackett; Raquel Formica; Valeria E Lorenc; Rishi Chadha; Minie Zhang; Sherri Van Everen; Nicholas Buss; Michele Fiscella; Olivier Danos; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2923. doi:

ARVO Annual Meeting Abstract July 2019

Co-operative Activities of VEGF and SDF-1 in Retina

DA LONG; Jikui Shen; Sean Hackett; Lili Lu; Zibran Hafiz; Qiang Gong; Peter A Campochiaro; Jingwen Yu; Jinpeng Wang; Scott Ferguson; Wen-Chuan Chou; Qin Yang; Hui Kang

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3262. doi:

ARVO Annual Meeting Abstract July 2019

A bispecific aptamer targeting both VEGF and Angiopoietin-2 for treating retinal diseases

Scott Ferguson; DA LONG; Qin Yang; Hui Kang; Jingwen Yu; Wen-Chuan Chou; Matthew Vukovich; Raquel Formica; Zibran Hafiz; Peter A Campochiaro; Jinpeng Wang; Qiang Gong

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3665. doi:

ARVO Annual Meeting Abstract July 2019

AXT107, a Peptide that Disrupts Integrins, Suppresses Vascular Leakage in the Setting of Ocular Inflammation

Raquel Formica; Sean Hackett; Zibran Hafiz; Adam Mirando; Jordan J Green; Aleksander S Popel; Niranjan B Pandey; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4073. doi:

Retina October 2018

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection

PDF

Yu Zhang; Hojjat Bazzazi; Raquel Lima e Silva; Niranjan B. Pandey; Jordan J. Green; Peter A. Campochiaro; Aleksander S. Popel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(12):5266-5276. doi: https://doi.org/10.1167/iovs.17-23632

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

Test-retest Reliability of MP1 and MAIA Microperimetry in Retinitis Pigmentosa

Mustafa Iftikhar; Jiangxia Wang; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):30. doi:

ARVO Annual Meeting Abstract July 2018

Progression of Retinitis Pigmentosa on Multimodal Imaging: The PREP-1 Study

Syed Mahmood Ali Shah; Mustafa Iftikhar; Bushra Usmani; Abanti Sanyal; Ramandeep Kaur; Marili Lemus; April Nefalar; Saleema A. Kherani; Simrat Sodhi; Saghar Bagheri; Etienne M Schonbach; Nadia Junaid; Peter A Campochiaro; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):45. doi:

ARVO Annual Meeting Abstract July 2018

Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents

Saleema A. Kherani; Roomasa Channa; Rimsha Shaukat; Olukemi Adeyemo; Mustafa Iftikhar; Adrienne Scott; Akrit Sodhi; James T Handa; Ingrid Zimmer-Galler; Adam Wenick; Sharon D Solomon; Mira Sachdeva; Catherine B Meyerle; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):825. doi:

ARVO Annual Meeting Abstract July 2018

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Hugo Quiroz-Mercado; David S Boyer; Peter A Campochiaro; Jeffrey S. Heier; Peter K Kaiser; Julie Kornfield; Baruch D Kuppermann; Vicken H Karageozian; Hampar L Karageozian; Lisa Karageozian; John Y Park; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1960. doi:

ARVO Annual Meeting Abstract July 2018

A small biomimetic collagen IV derived peptide reduces leakage and suppresses ocular neovascularization in mouse models

Raquel Formica; Valeria E Lorenc; Niranjan B Pandey; Ji-kui Shen; Jayoung Kim; Aleksander S Popel; Jordan Green; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3269. doi:

ARVO Annual Meeting Abstract July 2018

Hepatocyte growth factor (HGF) induces vascular leakage in the retina

Valeria E Lorenc; Raquel Formica; Seth Fortmann; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5308. doi:

ARVO Annual Meeting Abstract July 2018

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

Mitchell G Brigell; Victor H Gonzalez; Darren J Bell; Arshad M. Khanani; Barbara Withers; Laura Gambino; Peter A Campochiaro; Kevin G Peters; Steve Pakola

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1252. doi:

ARVO Annual Meeting Abstract July 2018

A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal Vascular Leakage

Kevin G Peters; Ji-kui Shen; Yuanyuan liu; Astrid Nottebaum; Dietmar Vestweber; Michael Flynn; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):199. doi:

ARVO Annual Meeting Abstract June 2017

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

Peter A Campochiaro; Raafay Sophie; Ann Clark; Na Lu; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4626. doi:

ARVO Annual Meeting Abstract June 2017

Murine Vitreous Tap (MurViTap): a novel technique to extract uncontaminated mouse vitreous humor, quantify retinal vascular permeability, and compare proteins secreted by diseased and normal retina

Seth Daniel Fortmann; Valeria E Lorenc; Sean Hackett; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5978. doi:

ARVO Annual Meeting Abstract June 2017

RGX-314, an AAV8 expressing an anti-VEGF protein, strongly suppresses subretinal neovascularization and vascular leakage in mouse models

Ji-kui Shen; yuanyuan liu; Seth Daniel Fortmann; Stephen Yoo; Karen Kozarsky; Jiangxia Wang; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):199. doi:

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Classification of disease severity in Retinitis Pigmentosa

Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors

Suprachoroidal AAV8-Vectored Gene Transfer Provides Widespread Transgene Expression in RPE and Retina

Co-operative Activities of VEGF and SDF-1 in Retina

A bispecific aptamer targeting both VEGF and Angiopoietin-2 for treating retinal diseases

AXT107, a Peptide that Disrupts Integrins, Suppresses Vascular Leakage in the Setting of Ocular Inflammation

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection

Test-retest Reliability of MP1 and MAIA Microperimetry in Retinitis Pigmentosa

Progression of Retinitis Pigmentosa on Multimodal Imaging: The PREP-1 Study

Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

A small biomimetic collagen IV derived peptide reduces leakage and suppresses ocular neovascularization in mouse models

Hepatocyte growth factor (HGF) induces vascular leakage in the retina

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal Vascular Leakage

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

Murine Vitreous Tap (MurViTap): a novel technique to extract uncontaminated mouse vitreous humor, quantify retinal vascular permeability, and compare proteins secreted by diseased and normal retina

RGX-314, an AAV8 expressing an anti-VEGF protein, strongly suppresses subretinal neovascularization and vascular leakage in mouse models

To View More...

You must be signed into an individual account to use this feature.